Thousands of men are set to receive a groundbreaking prostate cancer medication through the NHS in the coming weeks. Patients with localized cancer will soon have access to abiraterone in England as part of an expanded treatment initiative. Initially, around 2,000 individuals diagnosed in the last three months will benefit from the drug, with an estimated additional 7,000 men eligible each year.
Abiraterone, an oral prescription tablet, works by depriving the cancer cells of essential hormones for growth, effectively halting its spread. Recent NHS research has demonstrated an 86% survival rate after six years for patients on abiraterone, surpassing the 77% rate for standard treatments.
Prostate cancer is the most prevalent cancer among men in the UK, with over 55,000 new cases reported annually. Following Cancer Research UK data, NHS England has approved the use of abiraterone for a larger pool of eligible patients, reinforcing the government’s commitment to combatting the disease.
Health and Social Care Secretary Wes Streeting emphasized the importance of timely treatment for prostate cancer, highlighting the positive impact on patient outcomes. The availability of abiraterone is expected to offer thousands of men improved survival rates and valuable additional years with loved ones.
Professor Peter Johnson, National Clinical Director for Cancer at NHS England, hailed the life-changing potential of the treatment, providing hope for prolonging life expectancy and enhancing overall well-being. The NHS remains dedicated to delivering effective, evidence-based treatments, with several new prostate cancer therapies introduced over the past five years.
Meanwhile, researchers at the University of Cambridge are developing an advanced blood test that could revolutionize prostate cancer diagnosis and treatment planning. This innovative test identifies specific DNA markers released by tumors, enabling accurate assessment of cancer presence and severity without the need for invasive biopsies.
Men previously screened with the PSA test may benefit from this new blood test to assess cancer status based on marker levels, offering a less invasive alternative for monitoring and early detection.
